Patients affected by severe genetic and rare diseases Patients affected by severe genetic and rare diseases Patients affected by severe genetic and rare diseases

Transforming the
Lives of Patients

WITH SEVERE GENETIC AND RARE DISEASES

We are developing next generation products based on the transformative potential of gene therapy to treat patients with severe genetic and rare diseases. We have two clinical stage products in development for childhood cerebral adrenoleukodystrophy and beta-thalassemia/sickle cell disease, a preclinical oncology program in partnership with Celgene, a world-class team and a broadly applicable gene therapy platform READ MORE >>

spotlight


MAY 22, 2015

bluebird bio Announces Participation at the Jefferies 2015 Global Healthcare Conference

Read More

MAY 21, 2015

bluebird bio to Present LentiGlobin Clinical Data at 20th Congress of European Hematology Association

Read More

MAY 19, 2015

bluebird bio Announces Global Regulatory Strategy for LentiGlobin BB305 in Beta-Thalassemia Major

Read More

MAY 06, 2015

bluebird bio Reports First Quarter 2015 Financial Results and Business Updates

Read More

APRIL 30, 2015

bluebird bio Announces Participation at Two Upcoming Health Care Conferences

Read More

March 18, 2015

bluebird bio to Present at Alliance for Regenerative Medicine’s 3rd Annual Regen Med Investor Day

Read More